1. CUDC‑101 is a potential target inhibitor for the EGFR‑overexpression bladder cancer cells
   Zhenxing Wang et al, 2023, International Journal of Oncology CrossRef
2. Liquid chromatography–tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquid–liquid extraction
   Rolf W. Sparidans et al, 2016, Journal of Chromatography B CrossRef
3. Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines
   Karolin Ebert et al, 2020, BMC Cancer CrossRef
4. The Antibiotic and Antiprotozoal Agent Dibromopropamidine Dihydrochloride is a New EGFR Inhibitor and Potential Anticancer Drug for Bladder Cancer
   Kunbin Ke et al, 2022, ChemistrySelect CrossRef
5. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation
   Stéphanie van Hoppe et al, 2017, Pharmacological Research CrossRef
6. Prospects for precision therapy of bladder urothelial carcinoma
   Nuno Vau et al, 2017, Expert Review of Precision Medicine and Drug Development CrossRef
7. Identification of platinum resistance-related gene signature for prognosis and immune analysis in bladder cancer
   Sheng Li et al, 2023, Frontiers in Genetics CrossRef
8. Novel multi-targeted ErbB family inhibitor afatinib blocks EGF-induced signaling and induces apoptosis in neuroblastoma
   Xinfang Mao et al, 2017, Oncotarget CrossRef
9. Targeted therapies in the treatment of urothelial cancers
   Jeanny B. Aragon-Ching et al, 2017, Urologic Oncology: Seminars and Original Investigations CrossRef
10. Landscape of targeted therapies for advanced urothelial carcinoma
    Shihao Shang et al, 2024, Exploration of Targeted Anti-tumor Therapy CrossRef
11. Assessing Efficacy of Afatinib toward Elastic Matrix Repair in Aortic Aneurysms
    Simran Dayal et al, 2024, Tissue Engineering Part A CrossRef